Results 161 to 170 of about 10,402 (207)

Pegylated liposomal doxorubicin combined with cyclophosphamide and vincristine in pediatric patients with relapsed/refractory solid tumor: a single-arm, open-label, phase I study. [PDF]

EClinicalMedicine
Lu S, Wang J, Huang J, Sun F, Zhu J, Que Y, Li H, Guo Y, Cai R, Zhen Z, Sun X, Zhang Y.   +11 more
europepmc   +1 more source

Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study. [PDF]

Ther Adv Med Oncol
Hong Y, Peng J, Chen Q, Zhou Q, Xu F, Yao J, Zou Q, Yuan L, Li L, Long Q, Liao L, Liu M, Liu X, Zhang D, Wang S, Yi W.   +15 more
europepmc   +1 more source

Dorsal Hyperpigmentation Secondary to Pegylated Liposomal Doxorubicin

Journal of Oncology Medicine & Practice, 2016
Seddik Y, Barabino AD, Ruck S, Afqir S
openaire   +1 more source

Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study. [PDF]

BMC Cancer
Rubio MJ, Manzano A, de Sande LM, Estévez-García P, Gordon MDM, de Prado DS, de Aranguiz BHF, Guerra-Alia EM, Carbó-Bagué A, Romero I, Corbellas M, González-Haba A, Robles-Barraza CE, Martínez-García J, González-Martín A.   +14 more
europepmc   +1 more source

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial [PDF]

Annals of Oncology, 2012
The cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) in an adjuvant breast cancer treatment regimen is unknown. Women with resected node-positive or intermediate-risk node-negative HER2 overexpressing breast cancer and ...
Daniel Rayson, Thomas M Suter, J Van Den Bosch   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Role of pegylated liposomal doxorubicin in ovarian cancer

Gynecologic Oncology, 2005
Safe, effective treatments are needed for relapsed ovarian cancer. Goals include improving symptoms, enhancing quality of life, and prolonging survival. The plethora of agents currently available present difficult choices for physicians. The present effort seeks to examine the role of one of these agents, pegylated liposomal doxorubicin.A roundtable ...
J Tate Thigpen, Carol A Aghajanian, Susana M Campos   +2 more
exaly   +3 more sources

Pegylated Liposomal Doxorubicin: Tolerability and Toxicity

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
We evaluated the tolerability and toxicity attributed to pegylated liposomal doxorubicin (PL‐DOX) in women with recurrent or refractory ovarian cancer, and reviewed procedures to prevent or treat toxicity induced by the agent. Medical records of 13 women who received PL‐DOX between October 1997 and December 2000 were reviewed.
A L, Goram, P L, Richmond
openaire   +2 more sources

Striking Follicular Eruption to Pegylated Liposomal Doxorubicin

The American Journal of Dermatopathology, 2014
The adverse effects of pegylated liposomal doxorubicin are primarily cutaneous. The majority of these cutaneous side effects manifest as palmar-plantar erythrodysesthesia, whereas few reports of other cutaneous reactions exist in the literature. The authors report a case of an exuberant follicular eruption in a patient treated with pegylated liposomal ...
Julia, Dai, Robert, Micheletti, Misha, Rosenbach, Emily Y, Chu   +3 more
openaire   +2 more sources